← All trials
NCT03654833
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Jul 30, 2021
- Completion date
- Nov 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LeicesterLead sponsor
- Clovis OncologyCollaborator
- Eli LillyCollaborator
- RocheCollaborator
- MerckCollaborator
- University of LeicesterCollaborator
- The Christie NHS Foundation TrustCollaborator
- University of LeicesterStudy director
- BerGenBio ASACollaborator
- British Lung FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.